Sanofi (SNY) EBITDA Margin (2009 - 2026)
Sanofi's (SNY) quarterly EBITDA Margin came in at 9.03% in Q2 2026, down 572.0% year-over-year from 1.91% in Q2 2025, and down 55.27% quarter-over-quarter from 20.18% in Q1 2026.
Powered by 
Analysis
Sanofi (SNY) EBITDA Margin (2009 - 2026) Analysis & Trends
Sanofi has disclosed EBITDA Margin across 18 years of filings, most recently posting 9.03% for Q2 2026.
- In Q2 2026, EBITDA Margin fell 572.0% year-over-year to 9.03%; the TTM figure through Jun 2026 stood at 12.59% (down 784.0% YoY), while the FY2025 annual figure was 14.54%, down 311.0% from the prior year.
- EBITDA Margin came in at 9.03% for Q2 2026 at Sanofi, down from 20.18% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 122.84% in Q4 2023 to a low of 8.91% in Q4 2024.
- Average EBITDA Margin over 5 years is 26.91%, with a median of 21.0% recorded in 2026.
- Year-over-year, EBITDA Margin surged 10543 bps in 2023 and tumbled 11393 bps in 2024.
- Over 5 years, EBITDA Margin stood at 17.4% in 2022, then soared by 606 bps to 122.84% in 2023, then sank by 93 bps to 8.91% in 2024, then soared by 527 bps to 55.87% in 2025, then sank by 84 bps to 9.03% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 9.03% in Q2 2026, 20.18% in Q1 2026, and 55.87% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 28.21% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 37.86% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -3.52% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 32.97% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 28.37% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 9.03% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 41.69% |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 42.23% |
| 10 | Jazz Pharmaceuticals | 16.02 Bn | 14.40 Bn | 1.09 Bn | 20.54% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9.03% |
| Mar 31, 2026 | 20.18% |
| Dec 31, 2025 | 55.87% |
| Sep 30, 2025 | 22.84% |
| Jun 30, 2025 | 14.75% |
| Mar 31, 2025 | 23.09% |
| Dec 31, 2024 | 8.91% |
| Sep 30, 2024 | 29.11% |
| Jun 30, 2024 | 16.25% |
| Mar 31, 2024 | 13.84% |
| Dec 31, 2023 | 122.84% |
| Sep 30, 2023 | 26.84% |
| Jun 30, 2023 | 18.66% |
| Mar 31, 2023 | 24.10% |
| Dec 31, 2022 | 17.40% |
| Sep 30, 2022 | 21.82% |
| Jun 30, 2022 | 14.16% |
| Mar 31, 2022 | 24.78% |
| Dec 31, 2021 | 23.87% |
| Sep 30, 2021 | 29.06% |